Vaxart, Inc. Reorganizes Board Committees; Appoints Committee Chairs

What Happened

• Vaxart, Inc. announced on July 27, 2026 (filed via Form 8-K on July 28, 2026) that its Board approved a reorganization of the Nominating and Governance Committee and the Compensation Committee. The changes were recommended by the Nominating and Governance Committee and are effective August 1, 2026.
• Kevin P. Finney was named chair of the Nominating and Governance Committee and James B. Breitmeyer, M.D., Ph.D., was named chair of the Compensation Committee.

Key Details

• Date of board approval: July 27, 2026; effective date of committee changes: August 1, 2026.
• Nominating & Governance Committee members: Kevin P. Finney (chair) and David Wheadon, M.D.
• Compensation Committee members: James B. Breitmeyer, M.D., Ph.D. (chair), Elaine J. Heron, Ph.D., and W. Mark Watson.
• Item reported on the Form 8-K: 8.01 (Other Events).

Why It Matters

• Committee leadership determines who oversees board functions such as director nominations, corporate governance policies, and executive compensation reviews. These appointments signal who will lead that oversight going forward.
• For investors, changes in committee chairs are governance developments to watch because they can influence board priorities and how compensation and governance issues are handled, though the filing does not announce any immediate changes to executive pay or strategy.